Article Text

Download PDFPDF

4CPS-120 Erlotinib in non-small-cell lung cancer without epidermal growth factor receptor activating mutations
  1. D Yáñez Feria,
  2. IM Carrion Madroñal,
  3. MT Garrido Martinez,
  4. O Montero Pérez,
  5. MD Santos Rubio
  1. Juan Ramon Jimenez Hospital, Pharmacy, Huelva, Spain


Background Erlotinib is indicated in patients without epidermal growth factor receptor (EGFR)-activating mutations who have had at least one previous chemotherapy treatment that has failed and when other treatments are considered unsuitable.

Purpose To analyse the effectiveness and safety of erlotinib in non-small-cell lung cancer (NSCLC) in patients without EGFR-activating mutations

Material and methods A retrospective observational study was conducted in a third-level hospital. We included patients treated with erlotinib without EGFR-activating mutations from August 2012 to August 2018.

Following variables were recorded: age, sex, ECOG, histopathology, progression-free survival (PFS), smokers/non-smokers or ex-smokers, type of previous chemotherapy regimens, reported adverse events (AEs) and dose reductions between cycles.

We obtained data from electronic clinical records, the software where we register chemotherapy treatments (chemotherapy management software Oncogest) and the optimised computerised order entry ATHOS software.

AEs were classified according to the National Cancer Institute of Canada Common Toxicity Criteria v4.0.

Results Thirty-seven patients were included, with a median age of 64 years and 70% men. Fifty-seven per cent7 of patients presented ECOG 0 and the rest ECOG 1–2. Seventy-eight per cent of patients were smokers and/or ex-smokers. Ninety per centof patients received erlotinib as the second line of treatment or subsequently, and the median PFS was 9.3 weeks. Previous chemotherapy regimens used before erlotinib in NSCLC were: taxane-based-chemotherapy 60%, platinum-based-chemotherapy 83% and both 74%. Forty-eight per cent of patients had at least one AE during treatment. The most frequent was skin rash g1–2 (60%). Thirty per cent of patients had dose reductions due to toxicity.

Conclusion In our patients, erlotinib median PFS was lower than in the BR21 trial. It could be explained because our patients received more previous regimens of chemotherapy for metastatic disease as well as our sample size was smaller. Regarding safety, erlotinib was well tolerated and in most of the cases, the AEs did not force a dose reduction.

References and/or acknowledgements No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.